ClinicalTrials.gg
CompletedNCT03302871Updated Apr 24, 2020

Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A

A Phase 3 interventional study of Botulinum toxin type A and transcranial direct current stimulation in Cerebral Palsy, sponsored by Kocaeli University. Completed at 1 site in Turkey. Open to participants aged 5 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Kocaeli University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2016, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
5 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 327 studies in Cerebral Palsy with a site in Turkey — 43 open to participants now, 50 under way, none of them phase 3. Cerebral Palsy · Turkey.

Enrollment
51st of 189
40 · median 32
Started
2016
with 8 others
Phase 3
11 of 327
none open now
Registered
26th of 327
by date
Lead sponsor
8 of 327
Kocaeli University

Among the 327 studies in Cerebral Palsy with a site in Turkey, this one is the 51st largest by enrollment of the 189 interventional ones that give a count, is one of 9 that started in 2016, is one of 11 in phase 3, and was the 26th registered.

Cerebral Palsy

1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

43 of the 327 studies in Cerebral Palsy with a site in Turkey are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 269 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 234 (87%) stop at 75 or younger; 254 take children under 18; 52 take healthy volunteers.

This study: 5 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 327 studies in Cerebral Palsy with a site in Turkey, or all of them as a file.
02

Study summary

Evidence from literature support the use of Botulinum toxin A (BoNT-A) for upper limb spasticity management in children with cerebral palsy (CP). Constraint Induced Movement Therapy (CIMT) and Bilateral Intensive Training (BIT) are indicated as effective and complimentary treatments to improve motor function in these children. In a recent trial combined noninvasiv brain stimulation and CIMT enhanced therapy induced functional gains.

In this clinical trial the aim was to evaluate the effects of transcranial direct current stimulation (t-DCS) plus intensive hybrid training model of modified CIMT and BIT when integrated with BoNT-A treatment in children with unilateral CP.

Read the detailed description

Although BoNT-A is effective in spasticity management there is inconclusive evidence to support its usage for improvement in upper limb activity and function. Combination of BoNT-A and occupational therapy (OT) is found to be more effective then OT alone in reducing impairment, improving activity level and goal achievement. Intensive hybrid training models of CIMT and BIT and noninvasive brain stimulation are promising treatments on motor learning in children with CP. The aim of this clinical trial is to show the additional gains that could be provided by an integrated treatment of transcranial direct current stimulation (t-DCS) plus intensive hybrid training model of modified CIMT and BIT to BoNT-A injections in children with unilateral CP.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • cerebral palsy
  • botulinum toxin A
  • constraint induced movement therapy
  • transcranial direct current stimulation
04

Who can participate

Ages eligible
5 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of unilateral cerebral palsy
  • able to activate wrist and finger extensors
  • being scheduled for BoNT-A treatment for upper limb

Exclusion criteria

Exclusion Criteria:

  • significant loss of wrist and or fingers
  • history of orthopedic surgery to plegic upper limb
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    İntensive Therapy Group

    Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT

    Drug: Botulinum toxin type A · Device: transcranial direct current stimulation · Other: hybrid training model of CIMT and BIT

  • Active comparator
    Control Group

    Children who received Botulinum toxin type A to plegic upper limb would continue their usual care

    Drug: Botulinum toxin type A · Other: usual care

Interventions

  • Also known as: Botox, Dysport

  • Devicetranscranial direct current stimulation

    Also known as: noninvasiv brain stimulation

  • Otherhybrid training model of CIMT and BIT
  • Otherusual care

    Also known as: physical therapy

06

What researchers measure

Primary outcomes

  1. Assisting Hand Assesment

    Bilateral Hand Function Evaluation Instrument

    Time frame: 6 weeks

Secondary outcomes

  1. Jebsen Taylor Hand Function Test

    Unilateral Hand Function Evaluation Instrument

    Time frame: 6 weeks

Other outcomes

  1. Modifed Ashworth Scale

    Measurement of Tone

    Time frame: 6 weeks

  2. Active ROM of wrist dorsiflexion

    Measurement of active muscle function

    Time frame: 6 weeks

  3. Modified Tardieu Scale

    Measurement of spasticity

    Time frame: 6 weeks

07

Study locations

1 site
  • Kocaeli University
    Kocaeli, 41050, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2020, 48 months.

Of 17 phase 3 interventional studies under Cerebral Palsy, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 5, 2017
StartActual
Jan 18, 2016
Primary completionActual
Jan 30, 2020
CompletionActual
Jan 30, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03302871
Lead sponsor
Kocaeli University
Responsible party
Nigar Dursun (Professor, MD, Kocaeli University) — Principal investigator
First posted
Oct 5, 2017
Start date
Jan 18, 2016
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Apr 24, 2020

Study contacts

Nigar Dursun, MD
principal investigator · Kocaeli University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion